CJC-1295 / Ipamorelin Blend is a dual-peptide formulation combining CJC-1295, a synthetic analog of growth hormone-releasing hormone (GHRH), and Ipamorelin, a synthetic growth hormone-releasing peptide (GHRP). This blend is supplied for use in controlled laboratory environments to support research into peptide interactions and endocrine signaling mechanisms.

In preclinical and in vitro studies, CJC-1295 has been examined for its interaction with GHRH receptors and its role in modulating growth hormone signaling pathways, while Ipamorelin has been studied for its activity as a ghrelin receptor (GHS-R1a) agonist and its influence on peptide-mediated signaling processes. When combined, researchers investigate the complementary roles of these peptides in experimental models involving receptor activity, intracellular signaling cascades, and endocrine pathway dynamics. These investigations remain limited to laboratory and experimental conditions, and further research is required to fully understand their mechanisms and broader implications.

This blend is frequently associated with research topics such as growth hormone pathway analysis, peptide-based endocrine signaling, receptor interaction studies, and laboratory-grade synthetic peptides, making it relevant for scientific supply catalogs and research-focused platforms.

This material is supplied exclusively for research and laboratory use. It is not approved by the U.S. Food and Drug Administration for any therapeutic or clinical applications. This product is not intended to diagnose, treat, cure, or prevent any disease and must not be used for human or veterinary consumption.

All handling should be conducted by qualified professionals in appropriate research facilities, following applicable regulatory and safety standards.